NACHC urged HHS Secretary Xavier Becerra to hold drug manufacturers accountable for restricting shipments of 340B drugs to contract pharmacies.

News Alert

NACHC Asks HHS to Swiftly Punish Drug Makers for 340B Pricing Denials Involving Contract Pharmacies

The National Association of Community Health Centers (NACHC) strongly urged the U.S. Health and Human Services Secretary Xavier Becerra yesterday “to swiftly impose” fines on drug manufacturers that restrict shipments of 340B-purchased drugs to contract pharmacies and “hold manufacturers accountable for the breach” of their 340B pharmaceutical pricing agreements.

“Pharmaceutical manufacturers have callously and unlawfully chosen to restrict health centers’ access to 340B priced medications,” NACHC Interim President and CEO Rachel Gonzales-Hanson said in a June 16 letter to Becerra. “Health centers continue to experience devastating financial losses as we wait for final decisions in the alternative dispute resolution (ADR) process and ongoing federal court litigation.”

The National Association of Community Health Centers (NACHC) strongly urged the U.S. Health and Human Services Secretary Xavier Becerra yesterday “to swiftly impose” fines on drug manufacturers that restrict shipments of 340B-purchased drugs to contract pharmacies and “hold manufacturers accountable for the breach” of their 340B pharmaceutical pricing agreements.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer